Cite

    Hervé Tilly et al.. “Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study.” Lancet oncology, vol. 20, no. 7, 2019, pp. 998–1010. http://access.bl.uk/ark:/81055/vdc_100086499756.0x00000e